KZR — Kezar Life Sciences Income Statement
0.000.00%
Last trade - 00:00
- $57.51m
- -$133.79m
- $7.00m
- 19
- 34
- 31
- 18
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 7 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 37.3 | 43 | 54.7 | 71.2 | 118 |
Operating Profit | -37.3 | -43 | -54.7 | -71.2 | -111 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -35.1 | -41.7 | -54.6 | -68.2 | -102 |
Net Income After Taxes | -35.1 | -41.7 | -54.6 | -68.2 | -102 |
Net Income Before Extraordinary Items | |||||
Net Income | -35.1 | -41.7 | -54.6 | -68.2 | -102 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -35.1 | -41.7 | -54.6 | -68.2 | -102 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.84 | -0.949 | -1.04 | -1.01 | -1.32 |